Options strategist Rick Orford outlines a disciplined, top-down screening methodology to filter the market for optimal covered call candidates, emphasizing stock quality over mere premium yield.
Nasdaq Inc. reported stronger-than-expected fourth-quarter results, fueled by surging revenue from its technology solutions division and strategic AI initiatives, even as the company navigates a tighter margin environment.
Valley National Bancorp (VLY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, driven by robust core deposit growth and disciplined balance sheet management. The regional bank's leadership pointed to strategic tech investments and commercial loan demand as key pillars for its 2025 outlook.
While large-cap stocks offer stability, their massive scale often limits growth. We analyze one company whose competitive moat continues to widen and two others where valuation and market dynamics suggest caution is warranted.
The financial services sector, a traditional engine of economic growth, is underperforming the S&P 500 amid economic uncertainty. We examine three specific stocks—Invesco, Enova International, and Sixth Street Specialty Lending—that investors may want to approach with heightened caution.
While market gains have been concentrated in a handful of tech giants, a select group of companies across semiconductors, beauty, and banking have delivered consistent, triple-digit returns by mastering the fundamentals of growth, margins, and capital efficiency.
UN Secretary-General Antonio Guterres has issued a stark warning that the organization faces a severe liquidity crisis, with funds for its regular operations potentially running dry by July. The crisis is exacerbated by billions in unpaid dues, primarily from the United States.
Applied Optoelectronics (AAOI) is positioning itself at the forefront of the AI infrastructure build-out, securing a significant 800G transceiver order from a hyperscale customer and expanding its Texas manufacturing footprint. While these moves signal strong revenue momentum, they also amplify existing concerns over customer concentration and profitability.
Moody's Corporation bolsters its risk analytics arsenal with strategic acquisitions of Numerated Growth Technologies and CAPE Analytics, positioning itself at the center of a private credit market under the regulatory microscope.
For the first time in nearly a decade, Miami boasts more homes listed above $1 million than New York, underscoring a profound and sustained reorientation of luxury real estate demand toward Sun Belt markets.
Despite a six-month rally fueled by strong quarterly results, analysts point to sluggish long-term sales growth, weak cash flow, and declining returns on capital as reasons for caution, suggesting investors look elsewhere for opportunity.
While Jabil's stock has mirrored the S&P 500's recent gains, a closer look reveals underlying concerns over growth, profitability, and cash flow. We analyze the risks and spotlight a more compelling alternative in the digital advertising space.
Citizens JMP reaffirms its bullish stance on Salesforce, citing the explosive growth of its AI platform Agentforce and strong enterprise adoption as key catalysts for sustained outperformance.
As the Bank of England prepares for a leadership transition in 2028, a debate ignited by former Fed governor Kevin Warsh gains traction: should central banks shed ancillary roles and return to their core mission of price stability?
Under new CEO César Vargas, the family-owned group is breaking into five autonomous business units in a bid to boost agility and market responsiveness, as it eyes growth beyond its €900m turnover.
The global container shipping giant Ocean Network Express reported a net loss for its third fiscal quarter, citing soft demand and declining freight rates, particularly on key Asia-U.S. and Asia-Europe routes. The carrier anticipates a gradual recovery in the coming months.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Analyst Tara Bancroft of TD Cowen lowered the firm's price target on Geron Corporation (GERN) from $4 to $3, maintaining a Buy rating ahead of the biotech's fourth-quarter results. The move reflects a model update as the company navigates mixed commercial progress for its blood cancer drug RYTELO.
Piper Sandler raises its price target for Century Therapeutics (IPSC), highlighting the biotech firm's robust financial position extending into 2029 and an upcoming Investigational New Drug application for its lead cell therapy candidate, CNTY-813.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
